News for TG Therapeutics, Inc. (TGTX)

On March 5, 2025, Opaleye Management Inc. (Trades, Portfolio) made a strategic move by acquiring an additional 260,000 shares of Codexis Inc. (CDXS). This trans

**media[555305]**

TG Therapeutics Inc (TGTX) has announced its schedule for presenting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial on BRIUMVI® (u

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( TGTX), today announced the schedule of presentations highlighting data from the ULTIMATE I

On December 31, 2024, Opaleye Management Inc. (Trades, Portfolio) executed a significant transaction involving Ocular Therapeutix Inc. The firm reduced its hold

**media[538355]**

In our monthly Rare Stock Picks series, we're highlighting January 2025 investment picks. Click here for the list of January 2025 Buy recommendations.

TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

On January 22, 2025, Opaleye Management Inc. (Trades, Portfolio) executed a substantial reduction in its holdings of Harrow Inc., a U.S.-based eyecare pharmaceu

TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to deliver. Learn more on TGTX stock here.

TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth. Read more to see why I rate TGTX stock a strong buy.

We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts. In this article, we are going to take a look at where TG Therapeutics, Inc.

TG Therapeutics' stock rose 15% since my November buy recommendation, driven by Briumvi's strong performance and strategic developments, including a...

We recently published an article titled 10 Firms Post Impressive Gains on Tuesday. In this article, we are going to take a look at where TG Therapeutics Inc.

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

TG Therapeutics (TGTX) stock gains as company announces initial financial results for Q4 and full-year Briumvi sales in the U.S. Read more here.

TG Therapeutics, Inc. (TGTX), Tuesday announced preliminary fourth-quarter and full year 2024 results of Briumvi, a novel monoclonal antibody used for the treatment of relapsing forms of multiple sclerosis in adults.

**media[514523]**

Shares of Yum China Holdings Inc YUMC rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter EPS and revenues....